Stock & Company Details
Agenus Inc $AGEN
Price:
46,691,331
42M
$127M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-0.57
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
AGEN technical indicators
Latest Agenus Inc (AGEN) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
56.20 23.9%
MACD:
-0.08 31.6%
SMA 50:
$3.42 0.6%
SMA 200:
$3.67 0.1%
EMA 20:
$3.16 0.8%
Bollinger Bands:
3.44 / 2.82
Stochastic:
59.44 55.1%
ADX 14:
12.08 1.5%
ATR 14:
0.24 4.5%
CCI 20:
84.30 368.4%
OBV:
2.04M 47.8%
ROC 12:
3.33% 134.2%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Finance Bot
Ask your questions
Start by typing a question below.
